We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Therapeutic Gene Editing for Sickle Cell Disease

Article   Aug 19, 2019 | by Christopher Vakulskas, Integrated DNA Technologies

 
Therapeutic Gene Editing for Sickle Cell Disease
 
 
Advertisement
 

RELATED ARTICLES

The Coronavirus Outbreak

Article

On December 31, 2019, the first cases of a novel coronavirus were identified in Wuhan City, Hubei Province, China. Here, we curate a collection of news and content related to the outbreak.

READ MORE

Vaccine and Drug Development for COVID-19 – When the Cure Becomes the Problem

Article

The COVID-19 pandemic is happening in an age of social media where there is an expectation that the development of treatments should proceed and succeed as quickly as instant messaging. However, in reality, vaccines takes an average of two to five years to develop, and care must be taken in re-purposing existing drugs.

READ MORE

Pitfalls and Promises in Early Phase Oncology Trials

Article

Better cumulative decisions in early phases of drug development could lead to a greater chance of clinical success, as the correct dosage can be identified and tested in the right patient populations for the right early indicator. In this article, we delve into the current and future aspects of early-phase oncology trials.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE